NCT06660979: REINFORCE-EHR

Using Reinforcement Learning to Personalize Electronic Health Record Tools to Facilitate Deprescribing

Completed NA Last updated 2 April 2026

What this trial tests

NA trial testing Reinforcement learning in Aging in 1,249 participants. Completed in 27 March 2026.

Timeline

11 August 2025

Primary endpoint
27 March 2026

27 March 2026

Quick facts

Lead sponsor	Brigham and Women's Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	health services research
Enrollment	1,249
Start date	11 August 2025
Primary completion	27 March 2026
Estimated completion	27 March 2026
Sites	1 location across United States

Drugs / interventions tested

• Reinforcement learning

Conditions studied

• Aging — all drugs for Aging →

Sponsor

Brigham and Women's Hospital

Who can join

18 and older, any sex, with Aging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall goal of the proposed research is to refine and adapt and perform efficacy testing of a novel reinforcement learning-based approach to personalizing EHR-based tools for PCPs on deprescribing of high-risk medications for older adults. The trial will be conducted at Atrius Health, an integrated delivery network in Massachusetts, and will intervene upon primary care providers. The investigators will conduct a cluster randomized trial using reinforcement learning to adapt electronic health record (EHR) tools for deprescribing high-risk medications versus usual care. 70 PCPs will be randomized (i.e., 35 each to the reinforcement learning intervention and usual care \[no EHR tool\] in each arm) to the trial and follow them for approximately 30 weeks. The primary outcome will be discontinuation or ordering a dose taper for the high-risk medications for eligible patients by included primary care providers, using EHR data at Atrius. The primary hypothesis is that the personalized intervention using reinforcement learning will improve deprescribing compared with usual care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.